rTMS indicates repetitive transcranial magnetic stimulation.
Remission in patients without (A) and with (B) PTSD. Discussion of the effects of PTSD is provided in the Moderators of Treatment Effect section. MDD indicates major depressive disorder.
eTable 1. Adequacy of Antipsychotic and Antidepressant Trial by Treatment Group before Randomization
eTable 2. Adequacy of Antipsychotic and Antidepressant Trial by Treatment Group at End of Active Treatment
eTable 3. Urine Drug Screen Results
eTable 4. Effect of rTMS Treatment on Secondary Outcomes (Intention to Treat)
eTable 5. Effect of rTMS Treatment by Gender
eTable 6. Effect of rTMS Treatment on Secondary Outcomes (Intention to Treat) by PTSD Status, End of rTMS Treatment
eTable 7. Effect of rTMS Treatment on Secondary Outcomes (Intention to Treat) by PTSD Status, End of 24-Week Follow-up
Customize your JAMA Network experience by selecting one or more topics from the list below.
Yesavage JA, Fairchild JK, Mi Z, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(9):884–893. doi:10.1001/jamapsychiatry.2018.1483
Is repetitive transcranial magnetic stimulation an efficacious treatment for treatment-resistant major depression in patients who are veterans?
In this randomized clinical trial of 164 US veterans with depression, the overall remission rate was 39%, with no significant difference between the active and sham groups. Patients with comorbid posttraumatic stress disorder showed the least improvement.
These findings may reflect the importance of close clinical surveillance, rigorous monitoring of concomitant medication, and regular interaction with clinic staff in bringing about significant improvement in this treatment-resistant population.
Treatment-resistant major depression (TRMD) in veterans is a major clinical challenge given the high risk for suicidality in these patients. Repetitive transcranial magnetic stimulation (rTMS) offers the potential for a novel treatment modality for these veterans.
To determine the efficacy of rTMS in the treatment of TRMD in veterans.
Design, Setting, and Participants
A double-blind, sham-controlled randomized clinical trial was conducted from September 1, 2012, to December 31, 2016, in 9 Veterans Affairs medical centers. A total of 164 veterans with TRD participated.
Participants were randomized to either left prefrontal rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session) or to sham (control) rTMS treatment for up to 30 treatment sessions.
Main Outcomes and Measures
The primary dependent measure of the intention-to-treat analysis was remission rate (Hamilton Rating Scale for Depression score ≤10, indicating that depression is in remission and not a clinically significant burden), and secondary analyses were conducted on other indices of posttraumatic stress disorder, depression, hopelessness, suicidality, and quality of life.
The 164 participants had a mean (SD) age of 55.2 (12.4) years, 132 (80.5%) were men, and 126 (76.8%) were of white race. Of these, 81 were randomized to receive active rTMS and 83 to receive sham. For the primary analysis of remission, there was no significant effect of treatment (odds ratio, 1.16; 95% CI, 0.59-2.26; P = .67). At the end of the acute treatment phase, 33 of 81 (40.7%) of those in the active treatment group achieved remission of depressive symptoms compared with 31 of 83 (37.4%) of those in the sham treatment group. Overall, 64 of 164 (39.0%) of the participants achieved remission.
Conclusions and Relevance
A total of 39.0% of the veterans who participated in this trial experienced clinically significant improvement resulting in remission of depressive symptoms; however, there was no evidence of difference in remission rates between the active and sham treatments. These findings may reflect the importance of close clinical surveillance, rigorous monitoring of concomitant medication, and regular interaction with clinic staff in bringing about significant improvement in this treatment-resistant population.
ClinicalTrials.gov Identifier: NCT01191333
In any given year, major depressive disorder (MDD) occurs in 1 in 20 adults.1 Traditional treatments for MDD include a mix of pharmacologic and psychotherapeutic interventions, although up to 20% of patients fail to respond to these traditional treatments.2,3 Nonresponders can be classified as having treatment-resistant MDD (TRMD). Management of TRMD is complex and involves treatments such as monoamine oxidase inhibitors or electroconvulsive therapy (ECT). Although such approaches may be reasonable for patients with severe depression or patients with suicidality, for most patients with moderate TRMD symptoms, the decision to escalate treatments is more difficult because these treatments come with increased risks and associated costs. New TRMD treatments are needed, preferably without major safety concerns or adverse effects as seen with aggressive polypharmacy or ECT.
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive method of delivering brain stimulation using an electromagnetic coil that is positioned on the head near the brain region of interest. A systematic review and meta-analysis of studies shows efficacy in TRMD4 with effect sizes comparable to those in studies of contemporary antidepressant medications. Repetitive transcranial magnetic stimulation has fewer of the risks associated with ECT or the potential adverse effects and risks of monoamine oxidase inhibitors and is less expensive to administer than ECT.5 Thus, there is the potential for a significant advance in Veterans Affairs (VA) mental health care, with associated cost savings, if rTMS were to be shown as effective in the treatment of TRMD in VA patients.
To our knowledge, no other large-scale clinical trial has examined the efficacy of rTMS in VA patients with depression. This trial is an important next step because veterans may experience a different treatment response compared with civilians. This differential treatment response is well documented in studies of treatment of posttraumatic stress disorder (PTSD), in which veterans did not show the same treatment gains seen in civilians in both pharmacologic and psychotherapeutic trials.6,7 Veterans experience medical and psychiatric comorbidities that complicate their clinical presentation and can reduce their treatment response.8 Clinical trials in civilians often include a narrow subset of the patient population that is free from medical and psychiatric comorbidities; thus, it is unknown if these positive findings seen in civilian populations would translate into similar effects in VA practice settings. To address this question, we conducted a double-blind, sham-controlled trial of rTMS in veterans with TRMD.
Study participants were veterans with TRMD who received care in the VA health care system. Diagnosis of TRMD required both the classification of MDD as determined by the Structured Clinical Interview for DSM-IV and the failure of at least 2 prior pharmacologic interventions rated as adequate by a modified version of the Antidepressant Treatment History Form.9 The Antidepressant Treatment History Form findings are described in eTables 1 and 2 in Supplement 1. Veterans with comorbid PTSD and a history of substance use disorders were not excluded from study participation. Veterans had to be stable while receiving psychotropic medications for 4 weeks prior to randomization and continue receiving concomitant medications throughout rTMS treatment. Detailed inclusion/exclusion criteria can be found in the Box and drug screen results are in eTable 3 in Supplement 1. Study participants were recruited from a variety of settings where veterans receive mental health services in the VA health care system. These settings include traditional outpatient mental health clinics, primary care clinics, residential treatment programs, and inpatient settings at VA medical centers in Waco, Texas; Charleston, South Carolina; Cincinnati, Ohio; Palo Alto, California; Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania; San Francisco, California; Salt Lake City, Utah; and White River Junction, Vermont. The protocol is available in Supplement 2.
Between ages 18 and 80 y
Per the SCID for DSM-IV-TR, patients have an MDD diagnosis. HRSD score ≥20 no more than 7 days prior to randomization
Exhibit moderate level of resistance to antidepressant treatment defined, using the ATHF, as failure of ≥2 adequate medication trials
Duration of current episode of MDD, ≤10 y
Ability to obtain a motor threshold (should be determined at the end of the screening process)
Currently under the care of a VA psychiatrist
If receiving a psychotropic medication regimen, that regimen will be stable for ≥4 weeks prior to randomization and patient will be willing to continue receiving a stable regimen during the acute treatment phase
Has an adequately stable condition and environment to enable attendance at scheduled clinic visits
Women agree to use 1 of the following acceptable methods of birth control listed in the protocol: complete abstinence; oral contraceptive; levonorgestrel implant; medroxyprogesterone acetate; condom with spermicide; cervical cap with spermicide; diaphragm with spermicide; intrauterine device; surgical sterilization
Able to read, verbalize understanding, and voluntarily sign the informed consent form prior to performance of any study-specific procedures or assessments
Pregnancy or lactationa
Unable to be safely withdrawn, at least 2 wk before treatment commencement, from medications that substantially increase the risk of having seizures
Implanted device (deep brain stimulation) or metal in the brain
Mass lesion, cerebral infarct, increased intracranial pressure, or other active central nervous system disease, including a seizure disorder
Known current psychosis as determined by DSM-IV or SCID (Axis I, psychotic disorder, schizophrenia) or a history of a nonmood psychotic disorder
Known current bipolar I disorder as determined by SCID or a history of bipolar I disorder
Current amnestic disorders, dementia, Blessed Orientation-Memory-Concentration score >10,10,b delirium, or other cognitive disorders
Current substance abuse (not including caffeine or nicotine) as determined by positive toxicology screen, or by history via SCID, within 3 months prior to screening
Elevated risk of seizure due to TBI
Participation in concurrent clinical trial
Prior exposure to rTMS
Active current suicidal intent or plan as evidenced by a score of 4 or 5 on the suicidal ideation portion of the CSSRS11 or the endorsement of an actual attempt, interrupted attempt, or an aborted attempt in the past 6 months; all patients will be required to establish a written safety plan involving their primary VA psychiatrist and the treatment team before entering the clinical trial
Unstable cardiac disease or recent (<3 months previous) myocardial infarction
Refusal to sign consent for participation in the study
Abbreviations: ATHF, Antidepressant Treatment History Form; CSSRS, Columbia Suicide Severity Rating Scale; HRSD, Hamilton Rating Scale for Depression; MDD, major depressive disorder; rTMS, repetitive transcranial magnetic stimulation; SCID, Structured Clinical Interview for DSM Disorders; TBI, traumatic brain injury; VA, Veterans Affairs.
a This is a US Food and Drug Administration–required exclusion. In the future, if rTMS becomes a proven treatment for major depression, its safety in the context of pregnancy should be studied separately.
b Scores of 10 or greater are indicative of clinically significant cognitive impairment.
All 9 participating medical centers were reviewed and approved by the VA Central Institutional Review Board. Data were processed, managed, and analyzed by the VA Cooperative Studies Program Coordinating Center, Perry Point, Maryland. An independent data safety and monitoring board reviewed safety issues and study progress. All participants provided written informed consent; those who completed the study received financial compensation. Furthermore, all participants remained under the care of the primary mental health clinician and continued to receive stable doses of psychotropic medications throughout their participation in this trial.
Study participants were randomized to either left prefrontal rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session) or to sham (control) rTMS treatment for up to 30 treatment sessions. Repetitive transcranial magnetic stimulation was administered using a modified MagPro R30 (MagVenture) device with Cool-B65-A/P coil. The A (active) side of the unmarked coil delivered active treatment and the P (placebo) delivered sham treatment. For both groups, treatment was delivered in 5 session blocks over a period of 5 to 12 calendar days. Approximately 4000 stimulation pulses were delivered in each treatment session. Participants received between 20 and 30 sessions of rTMS. Participants who experienced remission after the initial 20 to 30 sessions received another 6 additional taper sessions that were delivered over a 3-week period.
Study participants were randomized to either active or sham treatment using an adaptive randomization scheme (biased coin procedure). On-site study staff (including site investigators, study coordinators, treaters, and raters) and participants were blinded to treatment group assignment. Each participant was assigned a number that was associated with a treatment group. Before each treatment session, study staff key-entered this number into the rTMS device to deliver the appropriate treatment (active or sham) for each participant. Detailed information on these measures and frequency of assessments is available in the full protocol (Supplement 2).12
The primary outcome of this intention-to-treat study was remission in depressive symptoms, which was defined as a score of 10 or less, indicating that depression is in remission and not a clinically significant burden, on the 24-item Hamilton Rating Scale for Depression (HRSD) (score range, 0-75; from not clinically significant to very severe depression) at the end of the acute treatment phase. Secondary outcomes included improvements in measures of depression (Montgomery-Åsberg Depression Rating Scale [score range, 0-50; from no symptoms to severe depression], Beck Depression Inventory-II [score range, 0-63; from minimal to severe depression]), PTSD (PTSD Checklist–Military [score range, 17-85; higher scores indicate more severe symptoms] and Clinician-Administered PTSD Scale for DSM-IV [score range, 0-136; from asymptomatic/few symptoms to extreme PTSD symptoms]), suicidal ideation (Beck Scale for Suicide Ideation [score range, 0-38; higher scores indicate great suicidality] and Columbia Suicide Severity Rating Scale [score range, 2-25; higher scores indicate higher intensity), and quality of life (Veterans RAND 36-item Health Survey [higher scores indicate better functioning]).
Primary analyses were performed using intent-to-treat principles on the 164 randomized patients. We performed logistic regression analyses to evaluate treatment efficacy that were adjusted for PTSD diagnosis, history of substance use disorder, and study site at the end of acute treatment and 24-week follow-up. Baseline characteristics between the 2 groups were compared using the Pearson χ2 test or Fisher exact test for categorical variables and analysis of variance or Wilcoxon signed rank test for continuous variables. For secondary analyses, the general linear model and logistic regression were used for the continuous and binary end points analyses, and a mixed linear model and generalized estimating equations were used to analyze the continuous and binary longitudinal measurements, respectively. All of the hypotheses were tested at the significance level of .05, using unpaired, 2-tailed tests. SAS, version 9.4 (SAS Institute Inc) was used for statistical analysis.
Participants were enrolled at 9 VA medical centers over a 4-year period with active enrollment extending from September 1, 2012, to May 31, 2016, and with data collection completed on December 31, 2016. We screened 342 patients and randomized 164 (Figure 1).
Of the 81 participants who were randomized to the active treatment group, 60 completed the study, 9 terminated during the treatment phase, and 12 withdrew during the follow-up phase. Of the 83 participants randomized to the sham treatment group, 65 completed the study, 9 terminated during the treatment phase, and 9 withdrew during the follow-up phase. The 5 main reasons for discontinuation included lost to follow-up/unable to contact, burden of visits/interviews, unable to return to clinic, adverse medical event, and withdrew from study. The groups did not significantly differ in terms of attrition, reasons for discontinuation, or number of adverse events.
Baseline demographic and clinical features of study participants by treatment group are reported in Table 1. Demographic characteristics did not differ significantly between the groups. There were no significant differences at baseline between the 2 groups other than on the Beck Depression Inventory in which the sham group rated themselves as being more depressed than the active treatment group.
The effects of rTMS treatment on primary and secondary outcomes are reported in Table 2. For the primary analysis of remission in the intention-to-treat sample (n = 164), there was no significant effect of treatment (odds ratio [OR], 1.16; 95% CI, 0.59-2.26; P = .67). Among the predefined covariates (substance abuse, PTSD status, and sites) in the logistic model, PTSD status was significantly related to the remission rate (OR, 0.47; 95% CI, 0.24-0.94; P = .03). At the end of the acute treatment phase, 33 of 81 participants (40.7%) in the active treatment group who finished the rTMS treatment achieved remission of depressive symptoms compared with 31 of 83 (37.4%) of those in the sham treatment group. Overall, 64 of 164 (39.0%) of the participants achieved remission. At the end of the follow-up phase, 16 (19.8%) of the active treatment group evidenced sustained remission compared with 13 (15.7%) of the sham treatment group.
When we examined the effects of the rTMS treatment on PTSD symptoms, there was no significant effect of treatment at the end of the acute treatment phase in either the Clinician Administered PTSD Scale for DSM-IV (treatment coefficient, 5.20; 95% CI, −0.49 to 10.89; P = .07) or the PTSD Checklist–Military (treatment coefficient, 2.68; 95% CI, −0.84 to 6.19; P = .13). Secondary outcomes are described in eTable 6 and eTable 7 in Supplement 1. These nonsignificant findings were also observed at the end of the follow-up phase. Furthermore, a similar pattern of nonsignificant findings was seen in measures of suicidality and quality of life at both the end of acute treatment and follow-up phases. A similar pattern of results was seen in both the Montgomery-Åsberg Depression Rating Scale and the Beck Depression Inventory (eTable 4 in Supplement 1).
Figure 2 highlights a potential treatment-moderating effect of PTSD diagnosis. When stratifying by presence or absence of PTSD comorbidity, 20 of 41 participants (48.8%) without PTSD achieved remission (a rate higher than the overall mean); only 13 of 40 participants with MDD (32.5%) with PTSD demonstrated remission (a rate lower than the overall mean). In the sham control condition, 18 participants (42.9%) with MDD without PTSD achieved remission compared with 13 participants (31.7%) with PTSD. Thus, rates of remission were higher for MDD (without PTSD) for active compared with sham conditions, whereas there was little difference for MDD with PTSD, and rates of remission were also lower in this comorbid group. Comorbidity also had a moderating effect on maintenance of remission. At the end of the follow-up phase, 14 participants (34.2%) with MDD (without PTSD) in the active treatment group maintained remission, compared with only 2 participants (5.0%) with MDD and PTSD. In the sham treatment condition, 3 participants (7.3%) with PTSD maintained remission, compared with 10 participants (23.8%) in the same treatment group without PTSD.
We also used a linear mixed-model approach to examine whether the lack of a significant difference between active and sham groups might have reflected missing data. The results of our primary and secondary analyses did not change. Also, to examine whether the lack of a significant difference between the active and sham groups reflected any attenuation in power due to our inclusion of covariates in our model (substance abuse, PTSD, and site), we conducted the primary analyses without these covariates included, and again, our findings remained unchanged.
Treatment-emergent adverse events did not differ significantly between treatment groups and were generally consistent with expected background medical issues in this population. The most common nonserious adverse events included nasopharyngitis (8 participants in both groups), depression (8 active and 3 sham participants), and falls (3 active and 7 sham participants). Headache, an adverse event commonly associated with rTMS, occurred in 15 active and 16 sham participants. There were 18 patients with abnormal results of hearing tests in each group, but this was believed to be an artifact of frequent, imprecise testing. The most common serious adverse event was suicidal ideation (3 active and 4 sham participants). No suicides or seizures occurred during the study and there were no deaths.
In this study of veterans with TRMD, we found that the delivery of rTMS while the participants were receiving other antidepressants was safe and well tolerated, with remission in 39.0% of all patients by the end of acute treatment. This finding is consistent with the observation that placebo response has been increasing over time in clinical trials of antidepressant medication.13 This remission rate is high compared with other studies of veterans with TRMD. A recent study of 3 pharmacologic augmentation strategies for veterans who did not respond to 1 antidepressant showed remission rates at 12 weeks that ranged from 22% to 29%.14 The higher remission rates seen in our rTMS study are even better because the patients undergoing rTMS were documented to have 2 failed trials of antidepressants, whereas the pharmacologic augmentation clinical trial required only 1 failed prior trial. Furthermore, this rTMS study showed that 16 of 33 (48.5%) of active rTMS participants with acute remission were still in remission 24 weeks later, as were 13 of 31 (41.9%) of those in the sham group.
We did not observe a significant difference in remission rates between the active rTMS and sham groups, which differs from previous rTMS trials in civilians. Specifically, the OPT-TMS trial reported remission rates in which 14% of participants who received active rTMS treatment achieved remission compared with 5% of those in the sham group (OR, 4.2; 95% CI, 1.32-13.24; P = .02).15 It is not surprising to find that these veterans had a differential treatment response as this is consistent with prior pharmacologic and psychotherapeutic trials in which veterans did not show the same treatment gains seen in civilians.6,7 Although the veterans in the present study are fairly representative of the veterans with TRMD seen in the VA, they are significantly more complex than participants recruited in civilian trials of rTMS on several factors. First, this study differed from most rTMS studies in the high proportion of men (80.5%), which is notable because women may have a better response rate to rTMS than men.16 The small number of female participants precluded formal statistical analyses of differential response; however, in our small sample, women generally had higher remission rates (eTable 5 in Supplement 1). Furthermore, compared with participants in the OPT-TMS trial, the veterans in the present trial were on average 8 years older (55.2 vs 47.1 years), had not responded to at least 2 prior antidepressant trials in their current depressive episode (compared with 1.51 on average), had numerous comorbid psychiatric disorders, including 49.4% with PTSD and 53.7% with a substance use disorder (compared with no comorbid Axis I disorders). These comorbidities increased the complexity of the patients, and thus their need for heightened clinical surveillance. Although the OPT-TMS researchers met with their participants with a similar frequency, the visits in the present study were almost twice the length of those in the OPT-TMS trial.
Our findings also differ from those of prior rTMS research in terms of the high rate of remission seen in both the active and sham groups. These high remission rates suggest that veterans’ expectations of improvement and extensive attention provided by the rTMS treatment team may have played a large role in the significant clinical improvements they experienced. As with other trials of rTMS, veterans in this study had daily meetings over 20 to 30 days with mental health professionals. However, unlike past trials of rTMS, veterans in this study were evaluated for medication adherence before each treatment session to confirm their adherence to a stable regimen of psychotropic medication, as this was a requirement for participation in the trial. Complementing the daily queries regarding medication adherence were the extensive evaluations of mood, suicidality, and substance use at the end of each treatment block and follow-up visit. Although all participants were followed up by mental health clinicians in the VA system, the regular contact with study staff was more extensive than is typically provided in outpatient mental health settings. This added attention may have interacted with the fact that this study was, to our knowledge, the first large rTMS clinical trial in which medications were included and contributed to enhanced adherence to pharmacologic treatments. Furthermore, 76.2% of the participants were unemployed and thus potentially socially isolated and/or inactive. This raises the possibility that the high remission rate may be in part due to the increased activity and contact with study staff, which is consistent with the substantial effects seen in trials of behavioral activation.17,18
Although prior studies of veterans suggested that they would have a response to psychiatric treatment different from civilians, we did not anticipate the differences in remission rates at follow-up seen in patients with TRMD with and without PTSD. In the active treatment, only 5.0% of patients with MDD and PTSD remained in remission at follow-up compared with 34.2% in those with MDD without PTSD. Similarly, in the sham condition, only 7.3% of patients with MDD and PTSD remained in remission at follow-up compared with 23.8% of those with MDD but without PTSD. Our ability to detect significant differences between these subgroups is limited by the sample size. Thus, futures studies should examine if such differences might be real. Furthermore, it is not known if the PTSD symptoms predated the current MDD episode, and thus would be the primary problem that is contributing to or exacerbating the depressive symptoms. Although PTSD is not a common comorbidity in rTMS studies of depressed civilians, anxiety disorder comorbidity has been found to be an indicator of poor outcome with rTMS.19 Treatment of PTSD may be more effective if targeting dysfunctional neural circuitry in this condition. For example, although studies has shown single-pulse TMS stimulation of the right ventrolateral prefrontal cortex during concurrent functional magnetic resonance imaging inhibited amygdala activity in PTSD, greater ability of right dorsolateral, prefrontal, single-pulse TMS/functional magnetic resonance imaging to inhibit amygdala activity in patients with PTSD is an indicator of better outcome with subsequent exposure therapy.20 Ultimately, we anticipate that overall outcomes will be improved by better aligning in future work particular aspects of rTMS interventions (eg, brain location, stimulation protocol including theta burst, TMS coil type) with biological and clinical heterogeneity, as exemplified here by PTSD comorbidity. Finally, we note that results of a recent study of ECT in veterans with MDD and PTSD showed a positive effect on both MDD and PTSD symptoms.21 Thus, the effects of rTMS and ECT appear to be quite different in this population of veterans.
Given this widespread use of rTMS in civilian populations and the high overall remission rates observed in this study, it would seem to be reasonable to use rTMS treatment in veterans. This is occurring in many sites across the nation. Like the present study, VA clinical use of rTMS involves a comprehensive approach to the patients, including pharmacotherapy, psychotherapy, and psychosocial support. The fact that there appears to be a positive response to ECT in veterans with MDD and PTSD suggests that such patients would do best with ECT.
The participants in this study are representative of patients seen in VA mental health care. These participants had multiple comorbidities, including PTSD and substance abuse. Given the complexity of our participants, a primary limitation of the project is that larger sample sizes are needed to discern subgroup effects. Furthermore, many advances have been made in the technical administration of rTMS in both MDD and PTSD since this study was conceived and the treatment would be done differently today.
This study supports the clinical observation that a combination of interventions including rTMS is effective for achieving symptom remission in 39.0% of veterans with MDD who were previously treatment resistant. This finding was particularly the case for the subset of veterans who did not have current PTSD as 1 of their comorbid characteristics where remission rate was 45.8%, whereas those with PTSD remission rate was 32.1%.
Achieving remission rates of 40% and over in treatment-resistant veterans is a clinically meaningful result warranting evaluation of such comprehensive approaches to treatment of patients with difficult-to-treat MDD within the VA. Future work with rTMS may show an enhanced effect when newer coil models, better stimulus targeting, biological markers of response, higher frequency rates of stimulation, and longer duration of treatment are implemented.
Corresponding Author: Jerome A. Yesavage, MD, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 3801 Miranda Ave, Palo Alto, CA 94304 (email@example.com).
Accepted for Publication: April 23, 2018.
Published Online: June 27, 2018. doi:10.1001/jamapsychiatry.2018.1483
Author Contributions: Dr Mi had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Yesavage, Fairchild, Biswas, Davis-Karim, Phibbs, Thase, Georgette, Huang, George.
Acquisition, analysis, or interpretation of data: Yesavage, Fairchild, Mi, Biswas, Davis-Karim, Phibbs, Forman, Williams, Etkin, Georgette, Beale, Huang, Noda, George.
Drafting of the manuscript: Yesavage, Fairchild, Forman, Thase, Georgette, Beale, Huang.
Critical revision of the manuscript for important intellectual content: Yesavage, Fairchild, Mi, Biswas, Davis-Karim, Phibbs, Forman, Thase, Williams, Etkin, Noda, George.
Statistical analysis: Mi, Biswas, Thase, Noda.
Obtained funding: Yesavage, Huang, George.
Administrative, technical, or material support: Yesavage, Fairchild, Biswas, Davis-Karim, Phibbs, Thase, Georgette, Beale, Huang, George.
Supervision: Yesavage, Fairchild, Biswas, Forman, Georgette, Huang, George.
Group Information: The Members of the CSP Research Group are CSP Planning Committee (responsibilities: study design): Jerome Yesavage, MD; Lawrence E. Adler, MD; David Avery, MD; Mark S. George, MD; Robert Rosenheck, MD; Harold A. Sackeim, PhD; Alan F. Schatzberg, MD; Stephen F. Bingham, PhD; Joseph F. Collins, ScD; Karen M. Jones, MS; Crystal L. Harris, PharmD; Grant D. Huang, MPH, PhD. Executive Committee (responsibilities: study conduct):
Jerome Yesavage, MD; J. Kaci Fairchild, PhD; Mark S. George, MD; Kousick Biswas, PhD; Zhibao Mi, PhD; Anne Davis-Karim, PharmD; Michael Thase, MD; Steven Forman, MD PhD; Ciaran Phibbs, PhD; David Pittman, MD; Gary Frazier, BA; Hal S. Wortzel, MD; Grant D. Huang, MPH, PhD (ex officio); Timothy J. O’Leary, MD, PhD (ex officio). Chairman’s Office, Veterans Affairs (VA), Palo Alto, California (responsibilities: study administration and oversight): Jerome Yesavage, MD (study chair); J. Kaci Fairchild, PhD (study co-chair); Mark S. George, MD (study co-chair); Gerald Georgette, RN, MSN, CCRC (national study coordinator); Tamara Beale, MA; Heather Taylor, MS. Cooperative Studies Program, VA Central Office, Washington, DC (Responsibilities: Study Administration and Oversight): Grant Huang, PhD (acting director).
Clinical Science Research & Development Service, Office of Research and Development, Washington, DC (Responsibilities: Study Administration and Oversight): Theresa Gleason, PhD (acting director). Cooperative Studies Program Coordinating Center, Perry Point, MD: Kousick Biswas, PhD (director) Zhibao Mi, PhD (biostatistician); Joseph F. Collins, ScD; Rebecca Anne Horney, BS; Xiaoli (Shirley) Lu; Joe Tadalan, BS. Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico (Responsibilities: Study Administration, Oversight of rTMS Administration and Safety Monitoring): Anne Davis-Karim, PharmD (study pharmacist); Crystal L. Harris, PharmD (study pharmacist) (deceased); Julia E. Vertrees, PharmD, BCPP (study pharmacist); David Pittman, MD (pharmaceutical project manager); Stuart R. Warren, PharmD, JD (center director); Stanley Johnson, MBA; Sharon George; Michael Chavez
Alexandra Scrymgeour, PharmD. Cooperative Studies Program Site Monitoring, Auditing and Resource Team (SMART), Albuquerque, NM (Responsibilities: Study Administration and Oversight of rTMS Safety Monitoring):
Carol L. Fye, RPh, MS (chief, SMART GCP Monitoring Group); Lawrence Calais, RN. Clinical Centers, Central Texas Veterans Health Care System, Waco, TX (Responsibilities: Data Collection): Peggy J. Pazzaglia, MD (site investigator); A. Renee Trujillo, MSN, RN, FNP, BC (site treater); Staley Justice, LMSW (site coordinator); Paul Hicks, MD; William A. Marcil, MD; Geoffrey May, MD; Kathryn McNair, RN; Christina Valenzuela, MPA; R. Bryce Williams, MS; Christine Kuhn, MS. Ralph H. Johnson VA Medical Center, Charleston, SC (Responsibilities: Data Collection): Christopher Pelic, MD (site investigator); Mark S. George, MD; Kathryn Beaver, RN, MS (site treater); Matthew Schmidt (site coordinator); Julia Arana West, MD; Tracey Greene, RN; Dennis Alex Wulfeck. Cincinnati VA Medical Center, Cincinnati, OH (Responsibilities: Data Collection): Muhammad Aslam, MD (site coinvestigator); Erik B. Nelson, MD (site coinvestigator); Jan DeMoisey, APRN (site treater); Deonna Suggs, BA (site coordinator); Daniel M. Beal, MD; Rebecca S. Gascoyne, FNP-BC; Debra S. Harris, MD; JoAnn Randolph, PhD, FNP, ANP; Mya Sabai, MD; Misty Wolfe, MPH. VA Palo Alto Health Care System, Palo Alto, California (Responsibilities: Data Collection): Jauhtai Joseph Cheng, MD (site investigator); Megan K. B. Reif, RN (site treater); Rebecca Hornik, MS, LPC (site coordinator); J. Wesson Ashford, MD PhD; Valerie Darcy, RN, PHN; Art Noda, MS; Allyson Rosen, PhD.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania (Responsibilities: Data Collection): Michael E. Thase, MD (site investigator); Mitchel A. Kling, MD; VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania (responsibilities: data collection): Steven D. Forman, MD, PhD (site investigator): Laurene Hardy, CRNP (site treater); Liubomir Andrei Pisarov, CCRC (site coordinator); Benjamin A. Congedo, BA; Karin Daniels, MA, PhD; Sarah E. Forster, PhD; Benjamin Meyers, BA; Suzanne Pierce, MA, CCRC. VA Salt Lake City Health Care System, Salt Lake City, Utah (Responsibilities: Data Collection: Perry Renshaw, MD, PhD (site coinvestigator); Phillip Gale, DO (site coinvestigator); Karen Stagnaro, RN (Site Treater); Tracy Hellem, PhD, RN (site treater); Rebekah Huber, PhD; Mallory Rogers, BS (site coordinator); Maryrose Bausckha, MD; Danielle Boxer, MS; Douglas G. Kondo, MD; Alexis Nelson, RN; Ubaid Zafar, MD; Kristen Fiedler, BS. San Francisco VA Health Care System, San Francisco, California (Responsibilities: Data Collection): Steven Lieske, MD, PhD (site investigator); Nicholas Rosenlicht, MD (co–site investigator); Charles Primich, PMHNP (site treater). White River Junction VA Medical Center, White River Junction, Vermont (Responsibilities: Data Collection): Bradley V. Watts, MD, PhD (site investigator); Trudi E. Silver, APRN (site treater); Janine Flanders, MPH (site coordinator); Julia McDougal Ronconi, APRN; Brian Shiner, MD, MPH.
Conflict of Interest Disclosures: Dr Etkin has equity holdings in Akili Interactive and Mindstrong Health for work unrelated to neurostimulation. No other conflicts were reported.
Funding/Support: This research was fully funded and supported by the Cooperative Studies Program, Office of Research and Development, US Department of Veterans Affairs.
Role of the Funder/Sponsor: The Cooperative Studies Program, Office of Research and Development, US Department of Veterans Affairs was responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.
Additional Contributions: Dr Yesavage obtained written permission to include the names of all individuals included in the Acknowledgment section and confirms that such permission has been obtained in the Authorship Form.